Cartesian Therapeutics, Inc. — Director's Dealing 2016

Jun 22, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2016-06-21

Reporting Person: Farokhzad Omid (Director, 10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	128004	Direct
Common Stock	3545	Indirect
Common Stock	202051	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$7.02	2026-03-08	Common Stock (25641)		Direct
Stock Option (right to buy)	$3.44	2022-01-23	Common Stock (61913)		Direct
Series E Convertible Preferred Stock	$		Common Stock (14244)		Indirect

Footnotes

F1: These securities are held by BioDynamics Core, L.P., which is managed by BioDynamics, LLC, of which the Reporting Person is a member. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

F2: These securities are held by SAF-SEL Trust, for which the Reporting Person's spouse serves as a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

F3: This option vests in 48 substantially equal monthly installments beginning on January 1, 2016.

F4: All shares underlying this option are fully vested.

F5: The preferred stock is convertible at any time, at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.